SAN DIEGO, June 12 /PRNewswire-FirstCall/ -- Clarity Imaging International, Inc. , a company that offers proven and emerging technologies to the medical community, today announced that it has signed a strategic alliance agreement with ValiRx plc a biopharmaceutical company based in England. The partnership enables both parties to cooperate in creating and exploiting technology transfer initiatives between the U.S. and Europe.
Specifically, the companies will look to cross license their products and technologies for distribution in their respective markets. Clarity Imaging, through an agreement with Bridgetech Holdings International, is targeting specific diagnostic and prognostic markets in the U.S. with products from Greater China. It has created strategic relationships in the U.S. healthcare supply chain to maximize product exposure. Furthermore, Clarity Imaging is leveraging ongoing relationships through Bridgetech including MD Anderson Cancer Centers and other world-renowned Cancer Centers.
"We are pleased and proud to be affiliated with ValiRx," stated John Relic, President and COO of Clarity Imaging. "The collaboration allows Clarity to gain access to the European biopharmaceutical market, furthering our growth in the medical diagnostic arena."
Dr Satu Vainikka, CEO of ValiRx, said: "We are developing a strong portfolio of new technologies in the therapeutics and diagnostic markets, with a specific focus on cancer. We are delighted to be partnering with an organization such as Clarity that has the potential to bring our technologies to US markets."
About Clarity Imaging International, Inc.
Clarity Imaging International, Inc. offers proven and emerging technologies to the medical community. The scope of our interest includes introducing diagnostic and imaging technologies, providing in-office diagnostic services and offering medical imaging center development, consultation and management. For additional information, please visit http://www.clmd.com.
About ValiRx Plc Global
ValiRx Plc is a biopharmaceutical development company that is building a portfolio of complementary cancer-related therapeutic and diagnostic technologies. It currently holds stakes in Cronos and Morphogenesis Inc; * Cronos holds licenses to two innovative and potentially market changing technologies, GeneICE and HyperGenomics; * Morphogenesis Inc. is developing a portfolio of cell therapy products for the treatment of chronic disorders. Its most advanced product, being ImmuneFx(TM) for which it recently received a patent from the US patent office. ValiRx Plc is listed on the London Stock Exchange's Alternative Investment Market, ticket VAL. For additional information, please visit ValiRx at http://www.valirx.com
Forward-Looking Statements.
Statements contained in this press release that are not statements of historical fact are "forward-looking statements" as that term is defined under federal securities laws, including, without limitation, all statements concerning expectations, beliefs, goals, intention or strategies for the future of Clarity Imaging International, Inc. Forward-looking statements may be identified by words such as "goals," "plans," "believes," "will," "expects" and other words of similar meaning used in conjunction with, among other things, discussions of future operations, financial performance, product development and new ventures. Many factors could cause actual events or results to differ materially from those expressed in any forward-looking statement. Investors are cautioned not to place any undue reliance on any forward-looking statements.
Contacts: Media Relations: Vince Heald, Beck Ellman Heald - 858-453-9600 vheald@behmedia.com Investor Relations: Redwood Consultants, LLC - 415-884-0348 MCC Global: Dana Smith - 801-816-2500
Clarity Imaging International, Inc.CONTACT: media relations, Vince Heald of Beck Ellman Heald,+1-858-453-9600, vheald@behmedia.com; or investor relations, RedwoodConsultants, LLC, +1-415-884-0348; or Dana Smith of MCC Global,+1-801-816-2500, all for Clarity Imaging International, Inc.
